La Fundaci\u00f3 Niemann-Pick Espanya ha lliurat a l\u2019IDIBELL i L\u2019Hospital de
\nBellvitge un xec per valor de 104.884 euros que es destinaran \u00edntegrament a la
\ncontinuaci\u00f3 d\u2019un estudi per determinar l\u2019efic\u00e0cia i seguretat del f\u00e0rmac Efavirenz
\nen el tractament del deteriorament cognitiu dels pacients d\u2019aquesta malaltia
\nminorit\u00e0ria d\u2019origen gen\u00e8tic per a la qual no existeix cura actualment. Els
\nprimers resultats de l\u2019assaig han aportat resultats for\u00e7a esperan\u00e7adors.
\nEl president de la fundaci\u00f3, Carmelo Fern\u00e1ndez, va lliurar el xec al Dr. Jordi
\nGascon, neur\u00f2leg i investigador principal del grup de malalties neurol\u00f2giques i
\nneurog\u00e8nica de l\u2019IDIBELL i l\u2019Hospital de Bellvitge, en un acte al centre, el
\npassat 8 de novembre. Tamb\u00e9 hi han assistit el Dr. Gabriel Capell\u00e0, director de
\nl\u2019Institut, i S\u00edlvia Cordom\u00ed, sots-gerent de l\u2019HUB i l\u2019Hospital de Viladecans, a
\nm\u00e9s d\u2019altres membres de la Fundaci\u00f3 Niemann-Pick.
\nEl Dr. Gasc\u00f3n ha agra\u00eft l\u2019esfor\u00e7 incansable de la Fundaci\u00f3 Niemann-Pick per
\nimpulsar la recerca com a eina de millora de la qualitat de vida dels pacients
\namb un assaig cl\u00ednic independent i realitzat amb totes les garanties. Realitzat
\namb 16 pacients (hi ha uns 27 a tot l\u2019estat), els primers resultats de
\nl\u2019administraci\u00f3 de l\u2019Efavirenz indiquen beneficis en escales de cognici\u00f3 i
\nconducta, sobretot en els pacients amb menys temps d\u2019evoluci\u00f3 de la malaltia.
\nPer aix\u00f2 ara s\u00f3n necessaris nous estudis per expandir els resultats, tal i com va
\ndestacar el Dr. Gasc\u00f3n.
\nL\u2019efavirenz \u00e9s un f\u00e0rmac antiretroviral utilitzat en el tractament per al VIH que
\nmillora la funci\u00f3 d\u2019un enzim que regula la distribuci\u00f3 de colesterol en la sinapsi,
\nel que el converteix en un gran candidat per al Niemann-Pick.
\nLa malaltia de Niemann-Pick\u00a0 \u00e9s una patologia neurodegenerativa heredit\u00e0ria
\nque \u00e9s caracteritza per l'acumulaci\u00f3 de diferents tipus de l\u00edpids (esfingomielina,
\ncolesterol) que provoca alteracions viscerals i al sistema nervi\u00f3s. Es divideix en
\nquatre tipus (A, B, C i D) depenent del gen afectat, cosa que determina un perfil
\ncl\u00ednic diferent. Els s\u00edmptomes m\u00e9s comuns s\u00f3n l\u2019afectaci\u00f3 cognitiva, l\u2019epil\u00e8psia,
\nel trastorn de conducta, la par\u00e0lisi vertical de la mirada, l\u2019at\u00e0xia, la distonia i
\nl\u2019esplenomeg\u00e0lia. Els tractaments existents s\u00f3n d\u2019una efic\u00e0cia discreta, per\u00f2
\nalenteixen l'evoluci\u00f3 de la malaltia.<\/p>\n
<\/p>\n
L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" El Dr. Gasc\u00f3n ha agra\u00eft l\u2019esfor\u00e7 incansable de la Fundaci\u00f3 Niemann-Pick per
\nimpulsar la recerca com a eina de millora de la qualitat de vida dels pacients.
\nL\u2019efavirenz \u00e9s un f\u00e0rmac antiretroviral utilitzat en el tractament per al VIH que
\nmillora la funci\u00f3 d\u2019un enzim que regula la distribuci\u00f3 de colesterol en la sinapsi,
\nel que el converteix en un gran candidat per al Niemann-Pick.<\/p>\n","protected":false},"author":8,"featured_media":26529,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[416,340,457],"tags":[],"class_list":["post-26528","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-malalties-neurologiques-i-neurogenetica","category-neurociencies","category-p-de-neurociencies"],"publishpress_future_action":{"enabled":false,"date":"2024-12-10 11:53:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26528"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26528\/revisions"}],"predecessor-version":[{"id":26530,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26528\/revisions\/26530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26529"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}